Kyowa Kirin
Japanese pharmaceutical and biotechnology company developing and commercializing prescription medicines, with major activities in oncology, immunology, nephrology, and rare diseases.
Last updated August 22, 2026
AI crawler reads
No AI crawler has read this profile since Oct 28, 2026.
Overview
Kyowa Kirin is a Japanese pharmaceutical and biotechnology company headquartered in Tokyo and operating as part of the Kirin Holdings group. Its modern identity emerged from the combination of Kyowa Hakko and Kirin Pharma, bringing together Kyowa Hakko Kogyo's fermentation, biotechnology, and pharmaceutical capabilities with Kirin's pharmaceutical business. The company was known as Kyowa Hakko Kirin for much of the period following the 2008 merger and adopted the Kyowa Kirin name in 2019. The company focuses primarily on prescription medicines rather than consumer health products. Its principal therapeutic interests have included oncology, immunology and allergy, nephrology, central nervous system disorders, and rare diseases. Kyowa Kirin also operates or has operated businesses involving biologics, biosimilars, active pharmaceutical ingredients, diagnostic reagents, analyzers, and companion diagnostics. Its international activities have expanded through subsidiaries, licensing arrangements, portfolio transactions, and acquisitions. A defining technological capability is the Potelligent antibody platform. The platform uses engineered Chinese hamster ovary cell lines with reduced fucosylation-related activity to produce afucosylated monoclonal antibodies designed to enhance antibody-dependent cellular cytotoxicity. Mogamulizumab, an antibody developed using this technology, received Japanese marketing approval in 2012 and became an important example of Kyowa Kirin's biologics strategy. Kyowa Kirin's marketed and historically marketed portfolio has included medicines such as darbepoetin alfa products, cinacalcet, mogamulizumab, pegfilgrastim products, granisetron, asparaginase, mitomycin, and fentanyl citrate products. Brand availability varies by country, regulatory status, commercialization rights, and local partner arrangements. The company has also pursued growth in rare diseases, including through its 2023 acquisition of Orchard Therapeutics, a British biopharmaceutical company specializing in gene therapies. The company has periodically reshaped its portfolio to concentrate resources on strategic medicines and growth platforms. In 2022 it announced plans to transfer 13 international established medicines into a joint venture with Grünenthal, a German pharmaceutical company with a strong pain-management business. In 2023 it announced the acquisition of Orchard Therapeutics for approximately US$478 million, subject to the transaction terms and applicable closing conditions. These moves illustrate Kyowa Kirin's effort to balance established products with specialty medicines, innovative biologics, and rare-disease opportunities. Kyowa Kirin is listed in Japan under ticker 4151 and has been included in the Nikkei 225. Although rooted in Japan, it markets products and maintains commercial or development operations across international markets. Its positioning is that of a specialist, science-led pharmaceutical company within the broader Kirin corporate group, with emphasis on differentiated medicines, biotechnology, and diseases where specialized treatment can address substantial unmet need.
History
Kyowa Kirin's corporate lineage extends to Kyowa Hakko Kogyo, which was established on July 1, 1949. Kyowa Hakko developed from Japan's fermentation and biochemical industries and built capabilities spanning pharmaceuticals, biotechnology, chemicals, and related products. This technical background later became important to the company's emphasis on biologic medicines and antibody engineering. A major structural change took place on October 1, 2008, when Kyowa Hakko Kogyo merged with Kirin Pharma. The resulting company was named Kyowa Hakko Kirin. The transaction joined Kyowa Hakko's pharmaceutical and biotechnology platform with the pharmaceutical activities associated with Kirin. Plans connected with the reorganization included separating the biochemical business into Kyowa Hakko Bio, allowing the pharmaceutical company and the biochemical operation to develop with distinct strategic priorities. Following the merger, Kyowa Hakko Kirin expanded its international specialty-pharmaceutical presence. One notable step was taken in July 2014, when its Scotland-based subsidiary ProStrakan Group acquired Archimedes Pharma from the Novo Nordisk Foundation. The transaction broadened the subsidiary's product and commercial capabilities in specialty medicines and reflected the company's use of international subsidiaries to build market access beyond Japan. The pharmaceutical group also developed a distinctive biologics technology platform known as Potelligent. The platform is based on production of afucosylated monoclonal antibodies in an engineered Chinese hamster ovary cell line in which FUT8 has been knocked out. By changing the antibody's glycosylation profile, the technology is intended to strengthen immune-cell engagement through antibody-dependent cellular cytotoxicity. Mogamulizumab became the most prominent product associated with the platform and obtained Japanese marketing approval in April 2012. The medicine helped establish Kyowa Kirin's reputation in antibody-based oncology and immunology treatments. In 2019, Kirin Holdings acquired a 95% interest in Kyowa Hakko Bio, a subsidiary connected with the group's biochemical operations. During the same period, the pharmaceutical company adopted the name Kyowa Kirin Co., Ltd., replacing Kyowa Hakko Kirin. The change emphasized the Kyowa Kirin identity while preserving its place within the Kirin Holdings corporate group. The company has maintained a broad prescription portfolio covering oncology, nephrology, immunology and allergy, central nervous system conditions, and supportive care. Examples include mogamulizumab, darbepoetin alfa products, cinacalcet, pegfilgrastim products, granisetron, asparaginase, mitomycin, and fentanyl citrate products. It has also participated in biosimilars, biologics manufacturing, active pharmaceutical ingredients, and diagnostic products. Individual products and rights have differed by territory and over time. During the 2020s, Kyowa Kirin pursued a more focused portfolio strategy. In November 2022 it announced plans to move 13 international established medicines into a joint venture with Grünenthal. The proposed structure was intended to give Grünenthal a larger pain-management and established-medicines portfolio while enabling Kyowa Kirin to concentrate capital and management attention on growth areas. In October 2023, Kyowa Kirin announced an agreement to acquire Orchard Therapeutics, a British biopharmaceutical company specializing in gene therapies for rare diseases. The reported transaction value was approximately US$478 million. The acquisition was intended to strengthen Kyowa Kirin's rare-disease capabilities and add a platform based on advanced genetic medicines. Together with its antibody technology and specialty pharmaceutical portfolio, the Orchard transaction illustrates the company's continuing shift toward differentiated medicines for patients with significant unmet medical needs. Today, Kyowa Kirin is a publicly listed Japanese pharmaceutical and biotechnology company headquartered in Tokyo. It remains part of Kirin Holdings, is associated with the Nikkei 225, and operates internationally through direct commercial organizations, subsidiaries, development activities, and partnerships.
- 2023
Orchard Therapeutics acquisition announced
[1]Kyowa Kirin announces the planned acquisition of Orchard Therapeutics to expand its rare-disease and gene-therapy activities.
- 2022
Established-medicines joint venture announced
[1]The company announces plans to transfer 13 international established medicines into a joint venture with Grünenthal.
- 2019
Corporate name changes to Kyowa Kirin
[1]Following Kirin Holdings' increased ownership of Kyowa Hakko Bio, Kyowa Hakko Kirin adopts the Kyowa Kirin name.
- 2014
Archimedes Pharma acquisition
[1]Subsidiary ProStrakan Group acquires Archimedes Pharma from the Novo Nordisk Foundation.
- 2012
Mogamulizumab receives Japanese approval
[1]Mogamulizumab, developed using Kyowa Kirin's Potelligent antibody platform, receives marketing approval in Japan.
- 2008
Merger with Kirin Pharma
[1]Kyowa Hakko Kogyo merges with Kirin Pharma on October 1, creating Kyowa Hakko Kirin.
- 1949
Kyowa Hakko Kogyo is established
[1]Kyowa Hakko Kogyo, the principal corporate predecessor of Kyowa Kirin, is established in Japan on July 1.
Products and positioning
A specialist, science-led pharmaceutical and biotechnology company focused on innovative prescription medicines, biologics, and specialty therapies.
Oncology and immunology biologic · 2012
Poteligeo
Poteligeo is the brand associated with mogamulizumab, a monoclonal antibody developed using Kyowa Kirin's Potelligent antibody-engineering platform. It represents the company's work in antibody-based treatment and is associated with oncology and immunologic disease applications. Approval, indications, and commercial availability vary by jurisdiction.
Nephrology and supportive-care medicine
Nesp / Aranesp / ESPO
These brand families are associated with darbepoetin alfa, an erythropoiesis-stimulating medicine used in settings involving anemia. Kyowa Kirin has included darbepoetin products among its nephrology and supportive-care offerings. Product names, marketing rights, and approved uses differ across countries.
Nephrology medicine
Regpara
Regpara is a brand associated with cinacalcet, a medicine used in specific disorders of mineral and parathyroid regulation, including applications connected with chronic kidney disease. It reflects Kyowa Kirin's long-standing focus on specialist nephrology care.
Supportive oncology medicine
Gran / Peglasta / Neulasta
This group includes products associated with pegfilgrastim and related granulocyte-colony-stimulating-factor treatments. They are used as supportive medicines in oncology care to help manage treatment-related neutropenia. Brand ownership, labels, and distribution arrangements vary by market.
Supportive oncology medicine
Sancuso
Sancuso is a granisetron product used for prevention of nausea and vomiting associated with chemotherapy in approved settings. It belongs to Kyowa Kirin's supportive-care portfolio serving oncology patients.
Oncology medicine
Leunase
Leunase is an asparaginase product used in oncology, particularly in treatment contexts where depletion of circulating asparagine is part of the therapeutic approach. Its indications and regulatory status depend on local approvals.
Specialty pain medicine
Abstral
Abstral is a fentanyl citrate product in the company's established-medicines portfolio. It is associated with specialist pain management and has been among the international established brands considered for portfolio restructuring.
Antibody-engineering technology
Potelligent platform
Potelligent is Kyowa Kirin's platform for producing afucosylated monoclonal antibodies. It uses an engineered CHO cell line with FUT8 activity knocked out or suppressed, a design intended to enhance antibody-dependent cellular cytotoxicity and support development of differentiated biologic medicines.
Brand decisions
2023
Acquire Orchard TherapeuticsM&ABackground
Kyowa Kirin sought to expand its rare-disease capabilities and gain access to a specialist gene-therapy company.
Action taken
Kyowa Kirin announced the acquisition of British biopharmaceutical company Orchard Therapeutics.
Aftermath
The transaction was intended to broaden Kyowa Kirin's rare-disease and advanced-therapy portfolio.
Reported acquisition value. Approximately US$478 million (October 2023 announcement)
2022
Transfer established medicines into a Grünenthal joint ventureStrategyBackground
Kyowa Kirin aimed to improve focus on growth businesses while Grünenthal sought to expand its established pain-management portfolio.
Action taken
The company announced plans to place 13 international established medicines into a new joint venture with Grünenthal.
Aftermath
The plan represented a portfolio-shaping move intended to provide financial and strategic benefits while transferring commercialization responsibility for selected brands.
2019
Adopt the Kyowa Kirin corporate nameStrategyBackground
Kirin Holdings increased its ownership of Kyowa Hakko Bio and the group continued to refine the relationship between its pharmaceutical and biochemical activities.
Action taken
Kyowa Hakko Kirin changed its name to Kyowa Kirin Co., Ltd.
Aftermath
The Kyowa Kirin name became the principal public identity for the pharmaceutical company within Kirin Holdings.
2014
Acquire Archimedes Pharma through ProStrakanM&ABackground
Kyowa Hakko Kirin sought to strengthen its international specialty-pharmaceutical presence through its Scotland-based subsidiary.
Action taken
ProStrakan Group acquired Archimedes Pharma from the Novo Nordisk Foundation.
Aftermath
The acquisition expanded the subsidiary's specialty-medicine portfolio and international commercial footprint.
Acquisition price. US$394 million (2014 transaction)
2008
Merge Kyowa Hakko Kogyo with Kirin PharmaM&ABackground
The two Japanese pharmaceutical businesses sought to combine their research, development, manufacturing, and commercial capabilities.
Action taken
The companies completed a merger on October 1, creating Kyowa Hakko Kirin and planning a distinct structure for the biochemical business.
Aftermath
The transaction created the corporate predecessor of Kyowa Kirin and established the basis for a broader international pharmaceutical group.
Recent events
- 2023
Kyowa Kirin agrees to acquire Orchard Therapeutics[1]
M&A
Kyowa Kirin announced the acquisition of British biopharmaceutical company Orchard Therapeutics for approximately US$478 million, with the stated strategic aim of expanding its rare-disease and gene-therapy portfolio.
- 2022
Kyowa Kirin plans established-medicines joint venture with Grünenthal[1]
M&A
Kyowa Kirin announced a plan to place 13 international established medicines into a new joint venture with Grünenthal, supporting portfolio focus and expanding Grünenthal's pain-management offering.
- 2019
Kirin Holdings increases ownership of Kyowa Hakko Bio[1]
M&A · Leadership change · Other
Kirin Holdings acquired a 95% stake in Kyowa Hakko Bio, and the pharmaceutical company changed its corporate name from Kyowa Hakko Kirin to Kyowa Kirin.
- 2014
ProStrakan acquires Archimedes Pharma[1]
M&A
Kyowa Hakko Kirin subsidiary ProStrakan acquired Archimedes Pharma from the Novo Nordisk Foundation, expanding its international specialty-pharmaceutical business.
- 2008
Kyowa Hakko Kogyo and Kirin Pharma merge to create Kyowa Hakko Kirin[1]
M&A · Other
The merger combined the pharmaceutical operations of Kyowa Hakko Kogyo and Kirin Pharma and created the corporate predecessor of today's Kyowa Kirin.
Sources3 sources
Cite this profile: Cite the canonical profile. /brand-wiki/kyowa-kirin · Editorial policy · How profiles are compiled